Allogeneic Stem Cell Transplant Effective for Refractory Cutaneous Lymphoma

According to a recent article published in the Journal of Clinical Oncology, an allogeneic stem cell transplant appears effective in the treatment of cutaneous T-cell lymphomas that have stopped responding to standard therapies.



Researchers from the City of Hope National Medical Center recently analyzed data from eight patients with cutaneous T-cell lymphomas, Sezary syndrome, and mycoses fungoides. These types of lymphomas affect the skin of patients. The data included patients who had stopped responding to several prior therapies. Four patients underwent an allogeneic stem cell transplant including high doses of therapy, and four underwent non-myeloablative allogeneic stem cell transplants.



All patients achieved a complete disappearance of detectable cancer. Two patients ultimately died from complications associated with treatment. At a follow-up of 56 months, the remaining six patients are alive and cancer-free. Patients treated with the non-myeloablative transplants suffered from fewer side effects. More Info

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap